4-(8-methoxy-1-(1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole → 4-(8-methoxy-1-((S)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole

HRID 2178586Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2178586
[CH3:1][O:2][C:3]1[C:12]([C:13]2[C:14]([CH3:19])=[N:15][O:16][C:17]=2[CH3:18])=[CH:11][C:10]2[N:9]=[CH:8][C:7]3[N:20]=[C:21]([CH:28]4[CH2:33][CH2:32][O:31][CH2:30][CH2:29]4)[N:22]([CH:23]([CH3:27])[CH2:24][O:25][CH3:26])[C:6]=3[C:5]=2[CH:4]=1>C(O)C>[CH3:1][O:2][C:3]1[C:12]([C:13]2[C:14]([CH3:19])=[N:15][O:16][C:17]=2[CH3:18])=[CH:11][C:10]2[N:9]=[CH:8][C:7]3[N:20]=[C:21]([CH:28]4[CH2:29][CH2:30][O:31][CH2:32][CH2:33]4)[N:22]([C@@H:23]([CH3:27])[CH2:24][O:25][CH3:26])[C:6]=3[C:5]=2[CH:4]=1

Komponenten

3

Edukt 1

HCID 712589164-(8-methoxy-1-(1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole

Produkt 1

HCID 712590474-(8-methoxy-1-((S)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazoleAusbeute 44,7 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 702EthanolLösungsmittel

Versuchsvorschrift

4-(8-methoxy-1-(1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole (85 mg) was dissolved in ethanol (ca. 4 ml) with heating and sonication. Injections (400 μl) were then made via plastic syringe. The fractions between 24 min and 26.5 min were collected and the combined fraction solutions were evaporated to dryness using a rotary evaporator (30° C. bath temp). The residue was transferred to a tared glass vial using ethanol (ca 12 ml). The solvent was then removed by evaporation under a stream of nitrogen gas (room temp) to give 4-(8-methoxy-1-((S)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole (38 mg).

Aufarbeitung

  1. temperaturewith heating
  2. customsonication
  3. customInjections (400 μl) were then made via plastic syringe
  4. customThe fractions between 24 min and 26.5 min were collected
  5. customthe combined fraction solutions were evaporated to dryness
  6. customa rotary evaporator (30° C. bath temp)
  7. customThe solvent was then removed by evaporation under a stream of nitrogen gas (room temp)

Quellen und Nachweise

ORD-Eintrag
ord-d0485999d0c94aa7a9fa1dec8f425f22
Quelldatensatz
uspto-grants-2015_06
Patentnummer
US09067936B2

Notizen zur Reaktion

Wird geladen…